Open AccessImmunotherapy Safe in Urothelial Carcinoma Patients Often Excluded
Author(s) -
Chuck Holt
Publication year - 2020
Publication title -
oncology times
Language(s) - English
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000696420.77951.c6
Subject(s) - medicine , atezolizumab , clinical trial , oncology , durvalumab , immunotherapy , population , bladder cancer , cancer , nivolumab , environmental health